Drug Update: First Person Dosed with Investigational Drug, VENT-03, for Lupus
The first drug of its kind to advance into clinical development, VENT-03 is an oral therapy designed to target and inhibit cGAS, a cell receptor linked to lupus and a broad range of other autoimmune diseases. The trial underway will assess the drug’s safety and how the medication affects the body.
Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.